Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

NETWORK × Endometrial Adenocarcinoma × nintedanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1 Genitourinary 1

Conditions

Thyroid Neoplasms 1 Sarcoma 1 Neoplasm Metastasis 1 Mesothelioma, Malignant 1 Endometrial Adenocarcinoma 1 Carcinoma, Medullary 1

Interventions

Doxorubicin 2 Cisplatin 2 pegfilgrastim 1 nintedanib 1 brivanib 1 Taxes 1 Radiotherapy 1 Radiation 1 Paclitaxel 1 Medroxyprogesterone Acetate 1 Medroxyprogesterone 1 Laparoscopy 1 Granulocyte Colony-Stimulating Factor 1 Gemcitabine 1 Filgrastim 1 ALK1-Fc fusion protein, human 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01225887 2017-10-09

Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

GOG Foundation

Phase 2 Completed

37 enrolled 11 charts

GenitourinaryGynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡